Mirza Abu-Sayeef, Horna Pedro, Teer Jamie K, Song Jinming, Akabari Ratilal, Hussaini Mohammad, Sokol Lubomir
Department of Internal Medicine, University of South Florida, Tampa, FL, United States.
Division of Hematopathology, Mayo Clinic, Rochester, MN, United States.
Front Oncol. 2020 Apr 21;10:514. doi: 10.3389/fonc.2020.00514. eCollection 2020.
Sézary syndrome (SS) is a genetically and clinically distinct entity among cutaneous T-cell lymphomas (CTCL). SS is characterized by more aggressive disease compared to the most common indolent type of CTCL, mycosis fungoides. However, there are limited available genomic data regarding SS. To characterize and expand current mappings of the genomic landscape of CTCL, whole exome sequencing (WES) was performed on peripheral blood samples from seven patients with SS. We detected 21,784 variants, of which 21,140 were novel and 644 were previously described. Filtering revealed 551 nonsynonymous variants among 525 mutated genes-25 recurrent mutations and 1 recurrent variant. Several recurrently mutated genes crucial to pathogenesis pathways, including Janus kinase (JAK)/signal transducers and activators of transcription (STAT), peroxisome proliferator-activated receptors (PPAR), PI3K-serine/threonine protein kinases (AKT), and fibroblast growth factor receptors (FGFR), were identified. Furthermore, genetic mutations spanned both known and novel genes, supporting the idea of a long-tail distribution of mutations in lymphoma. Acknowledging these genetic variants and their affected pathways may inspire future targeted therapies. WES of a limited number of SS patients revealed both novel findings and corroborated complexities of the "long-tail" distribution of previously reported mutations.
Sézary综合征(SS)是皮肤T细胞淋巴瘤(CTCL)中在遗传学和临床上都具有独特性的实体。与最常见的惰性CTCL类型蕈样肉芽肿相比,SS的疾病侵袭性更强。然而,关于SS的可用基因组数据有限。为了表征和扩展当前CTCL基因组格局的图谱,我们对7例SS患者的外周血样本进行了全外显子组测序(WES)。我们检测到21,784个变异,其中21,140个是新变异,644个是先前已描述的变异。筛选后在525个突变基因中发现了551个非同义变异——25个复发性突变和1个复发性变异。我们鉴定出了几个对发病机制途径至关重要的复发性突变基因,包括Janus激酶(JAK)/信号转导子和转录激活子(STAT)、过氧化物酶体增殖物激活受体(PPAR)、PI3K-丝氨酸/苏氨酸蛋白激酶(AKT)和成纤维细胞生长因子受体(FGFR)。此外,基因突变涵盖了已知基因和新基因,支持了淋巴瘤中突变呈长尾分布的观点。认识到这些遗传变异及其影响的途径可能会启发未来的靶向治疗。对有限数量的SS患者进行的WES揭示了新的发现,并证实了先前报道的突变“长尾”分布的复杂性。